Conclusion
prostate cancer
PATHOLOGY, PROSTATE CANCER, PROSTATE
This unique follow up study highlights the outcome of a pre-biopsy EPI score and how it changes the clinical outcome for patients even 2.5 years later compared to a blinded control arm that could utilize any standard of care parameters, including other biomarkers. The prior EPI clinical utility study trial demonstrated that EPI significantly impacts prostate biopsy shared decision-making during the decision process. This study extends the initial analysis by demonstrating that EPI continues to contribute risk information over time that is not available with SOC parameters. Men with EPI low-risk scores safely defer testing for longer and, based on biopsy pathology, remain low-risk for years. Only 1.2% of patients in the EPI arm and 3.4% in the combined cohort defined as EPI low-risk had ≥GG3 prostate cancer across multiple biopsies at 2.5 years. Overall, this study demonstrates that a pre-biopsy EPI test leads to better outcomes even when followed for 2.5 years after the initial biopsy decision-making process.